|
[1] Scheinfeld
N. A comprehensive review and evaluation of the side effects of the tumor
necrosis factor alpha blockers etanercept, infliximab and adalimumab[J]. J
Dermatolog Treat, 2004, 15(5):280-294. DOI: 10.1080/09546630410017275.
[2] 全国儿童风湿病协作组.依那西普治疗幼年特发性关节炎的专家共识[J].临床儿科杂志,2011,29(6):587-591.
DOI:10.3969/j.issn.1000-3606.2011.06.025.
[3] 周志轩,苏改秀.生物制剂在幼年特发性关节炎的应用[J].中国实用儿科杂志,2021,36(1):19-23. DOI:10.19538/j.ek2021010605.
[4] 中华医学会消化病学分会炎症性肠病学组儿科协作组.抗肿瘤坏死因子-α单克隆抗体治疗儿童克罗恩病的专家共识[J].中华炎性肠病杂志,2021,5(2):114-124.
[5] 周娟,张宇,丁媛,等.英夫利昔单抗治疗幼年特发性关节炎的疗效[J].中华实用儿科临床杂志,2014,29(9):655-658.
DOI:10.3760/j.issn.2095-428X.2014.09.005.
[6] Mori M. Clinical trial of the infliximab
for Kawasaki disease that an effect is inadequate for by existing treatment in
Japan[J].Rheumatology (United Kingdom), 2017,56:65.
[7] Hernandez-Santana YE, Giannoudaki E,
Leon G, et al. Current perspectives on the interleukin-1 family as targets for
inflammatory disease[J]. Eur J Immunol, 2019, 49(9):1306-1320. DOI:
10.1002/eji.201848056.
[8] Ringold S, Weiss PF, Beukelman T, et al.
2013 update of the 2011 American College of Rheumatology recommendations for
the treatment of juvenile idiopathic arthritis: recommendations for the medical
therapy of children with systemic juvenile idiopathic arthritis and
tuberculosis screening among children receiving biologic medications[J].
Arthritis Rheum, 2013, 65(10):2499- 2512. DOI: 10.1002/art.38092.
[9] Berghen N, Vulsteke JB, Westhovens R, et
al. Rituximab in systemic autoimmune rheumatic diseases: indications and
practical use[J]. Acta Clin Belg, 2019, 74(4):272-279. DOI:
10.1080/17843286.2018.1521904.
[10] Fanouriakis A, Kostopoulou M, Alunno A,
et al. 2019 update of the EULAR recommendations for the management of systemic
lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6):736-745. DOI:
10.1136/annrheumdis-2019-215089.
[11] Vincent FB, Morand EF, Schneider P, et
al. The BAFF/APRIL system in SLE pathogenesis[J]. Nat Rev Rheumatol, 2014,
10(6):365-373. DOI: 10.1038/nrrheum.2014.33.
[12] 张高福,王墨.儿童狼疮性肾炎的生物制剂治疗现状[J].中华实用儿科临床杂志,2021,36(17):1296-1300. DOI:10.3760/cma.j.cn101070-20210721-00860.
[13] 蔡雷,任大明.一对重要的免疫调节分子:CTLA-4及其抗体[J].中国免疫学杂志,2004,20(5):363-366.
[14] Hosseini A, Gharibi T, Marofi F, et al.
Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune
diseases[J]. J Cell Physiol, 2020, 235(9):5903-5924. DOI: 10.1002/jcp.29593.
[15] Nash P, Kerschbaumer A, Dörner T, et al.
Points to consider for the treatment of immune-mediated inflammatory diseases
with Janus kinase inhibitors: a consensus statement[J]. Ann Rheum Dis, 2021,
80(1):71-87. DOI: 10.1136/annrheumdis-2020-218398.
[16] Ruperto N, Brunner HI, Zuber Z, et al.
Pharmacokinetic and safety profile of tofacitinib in children with
polyarticular course juvenile idiopathic arthritis: results of a phase 1,
open-label, multicenter study[J]. Pediatr Rheumatol Online J, 2017, 15(1):86.
DOI: 10.1186/s12969-017-0212-y.
[17] Sabbagh S, Almeida de Jesus A, Hwang S,
et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis
using tofacitinib[J]. Brain, 2019, 142(11):e59. DOI: 10.1093/brain/awz293.
[18] Dumaine C, Bekkar S, Belot A, et al.
Infectious adverse events in children with Juvenile Idiopathic Arthritis
treated with Biological Agents in a real-life setting: data from the
JIRcohorte[J]. Joint Bone Spine, 2020, 87(1):49-55. DOI:
10.1016/j.jbspin.2019.07.011.
[19] Choi JY, Chung JE, Park JH, et al.
Surveillance of adverse drug events associated with etanercept prescribed for
juvenile idiopathic arthritis in a single center up to 9-years: a retrospective
observational study[J]. PLoS One, 2018, 13(11):e0204573. DOI:
10.1371/journal.pone. 0204573.
[20] Canakinumab/infliximab/tocilizumab[J].Reactions
Weekly, 2021,1845(1): 111.
[21] 贺业群,刘一品.溃疡性结肠炎内科治疗的研究进展[J].国际医药卫生导报,2021,27(18):2831-2835.
DOI:10.3760/cma.j.issn.1007-1245.2021.18.008.
|
